EP0696193A4 - 12-lipoxygenase de leucocytes humains, mediation exercee par la voie metabolique de cette enzyme et consequences de cette action - Google Patents

12-lipoxygenase de leucocytes humains, mediation exercee par la voie metabolique de cette enzyme et consequences de cette action

Info

Publication number
EP0696193A4
EP0696193A4 EP94919966A EP94919966A EP0696193A4 EP 0696193 A4 EP0696193 A4 EP 0696193A4 EP 94919966 A EP94919966 A EP 94919966A EP 94919966 A EP94919966 A EP 94919966A EP 0696193 A4 EP0696193 A4 EP 0696193A4
Authority
EP
European Patent Office
Prior art keywords
pathway
aii
mediation
lipoxygenase
consequences
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP94919966A
Other languages
German (de)
English (en)
Other versions
EP0696193A1 (fr
Inventor
Jerry L Nadler
Rama Devi Natarajan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
City of Hope
Original Assignee
City of Hope
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by City of Hope filed Critical City of Hope
Publication of EP0696193A1 publication Critical patent/EP0696193A1/fr
Publication of EP0696193A4 publication Critical patent/EP0696193A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0069—Oxidoreductases (1.) acting on single donors with incorporation of molecular oxygen, i.e. oxygenases (1.13)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y113/00—Oxidoreductases acting on single donors with incorporation of molecular oxygen (oxygenases) (1.13)
    • C12Y113/11—Oxidoreductases acting on single donors with incorporation of molecular oxygen (oxygenases) (1.13) with incorporation of two atoms of oxygen (1.13.11)
    • C12Y113/11012—Linoleate 13S-lipoxygenase (1.13.11.12)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y113/00—Oxidoreductases acting on single donors with incorporation of molecular oxygen (oxygenases) (1.13)
    • C12Y113/11—Oxidoreductases acting on single donors with incorporation of molecular oxygen (oxygenases) (1.13) with incorporation of two atoms of oxygen (1.13.11)
    • C12Y113/11031—Arachidonate 12-lipoxygenase (1.13.11.31), i.e. lipoxygenase-type-12
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

On décrit la découverte et la régulation d'une isoforme de 12-lipoxygénase (h1 12-LO) exprimée dans les tissus humains et d'une isoforme similaire exprimée dans les cellules des muscles lisses vasculaires de porc (PVSMC). On décrit différents ribozymes et composés chimiques inhibiteurs de la voie métabolique de la lipoxygénase hl 12-LO. L'action exercée par la voie métabolique de la 12-LO dans l'hypertrophie induite par l'angiotensine II a été mise en évidence. On montre que la culture en présence de hautes concentrations de glucose (HG) potentialise les effets stimulants de l'angiotensine II et de l'acide hydroxyeicosatétraénoïque (HETE) dans les muscles lisses vasculaires. Un aspect spécifique de l'invention concerne la découverte que l'activation de la voie métabolique de la 12-LO dans les muscles lisses vasculaires accentue la réponse hypertrophique vasculaire induite par l'angiotensine II chez les patients souffrant de diabète sucré. On décrit un traitement chez l'homme utilisant la médiation exercée par la voie métabolique de l'enzyme h1 12-LO.
EP94919966A 1992-08-28 1994-01-04 12-lipoxygenase de leucocytes humains, mediation exercee par la voie metabolique de cette enzyme et consequences de cette action Withdrawn EP0696193A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93666092A 1992-08-28 1992-08-28
PCT/US1994/000089 WO1995018609A1 (fr) 1992-08-28 1994-01-04 12-lipoxygenase de leucocytes humains, mediation exercee par la voie metabolique de cette enzyme et consequences de cette action

Publications (2)

Publication Number Publication Date
EP0696193A1 EP0696193A1 (fr) 1996-02-14
EP0696193A4 true EP0696193A4 (fr) 1996-11-27

Family

ID=25468927

Family Applications (2)

Application Number Title Priority Date Filing Date
EP93921232A Withdrawn EP0621895A4 (en) 1992-08-28 1993-08-26 Inhibition of the formation or activity of human leukocyte 12-lipoxygenase pathway.
EP94919966A Withdrawn EP0696193A4 (fr) 1992-08-28 1994-01-04 12-lipoxygenase de leucocytes humains, mediation exercee par la voie metabolique de cette enzyme et consequences de cette action

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP93921232A Withdrawn EP0621895A4 (en) 1992-08-28 1993-08-26 Inhibition of the formation or activity of human leukocyte 12-lipoxygenase pathway.

Country Status (5)

Country Link
EP (2) EP0621895A4 (fr)
JP (1) JPH07500254A (fr)
AU (2) AU674339B2 (fr)
CA (1) CA2077461C (fr)
WO (2) WO1994005777A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6191169B1 (en) 1992-08-28 2001-02-20 City Of Hope Human leukocyte 12-lipoxygenase and its role in the pathogenesis of disease states
WO1996034943A1 (fr) * 1995-05-04 1996-11-07 City Of Hope 12-lipoxygenase leucocytaire humaine et son role dans la pathogenese d'etats pathologiques
AUPP349098A0 (en) * 1998-05-13 1998-06-04 South Eastern Sydney Area Health Service A method of monitoring pancreatic tissue viability
US6103496A (en) * 1998-05-29 2000-08-15 Vanderbilt University Isolated and purified 12R-lipoxygenase protein and nucleic acids
US6582957B1 (en) 1999-04-12 2003-06-24 Lexicon Genetics Incorporated Lipoxygenase proteins and polynucleotides encoding the same
CN1301847A (zh) * 1999-12-27 2001-07-04 上海博德基因开发有限公司 一种新的多肽——脂肪氧化酶10和编码这种多肽的多核苷酸
CN1313389A (zh) * 2000-03-15 2001-09-19 上海博德基因开发有限公司 一种新的多肽——人脂肪氧化酶9和编码这种多肽的多核苷酸

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4849445A (en) * 1983-12-14 1989-07-18 The Upjohn Company Method for treating or preventing deep vein thrombosis using lipoxygenase inhibitors

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0815851B2 (ja) * 1987-10-09 1996-02-21 日産自動車株式会社 差動制限装置

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4849445A (en) * 1983-12-14 1989-07-18 The Upjohn Company Method for treating or preventing deep vein thrombosis using lipoxygenase inhibitors

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CAROLINE P. BELL-QUILLEY ET AL.: "Retrovascular actions of Angiotensin II in the isolated kidney of the rat: Relationship to lipoxygenases", THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 267, no. 2, November 1993 (1993-11-01), pages 676 - 682, XP000602385 *
J.A. KIM ET AL.: "Evidence that a leukocyte type of 12-lipoxygenase is expressed in normal human vascular and mononuclear cells", CLINICAL RESEARCH, vol. 41, no. 2, 1993, pages 148A, XP000601185 *
R. NATARAJAN ET AL.: "Tumor necrosis factor and Interleukin-1 are potent inhibitors of Angiotensin-II-induced Aldosterone synthesis", ENDOCRINOLOGY, vol. 125, no. 6, December 1989 (1989-12-01), pages 3084 - 3089, XP000601177 *
R. NATARAJAN ET AL.: "Vascular smooth muscle cells exhibit increased growth in response to elevated glucose", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 187, no. 1, 31 August 1992 (1992-08-31), ORLANDO, FL US, pages 552 - 560, XP002013499 *
RAMA NATARAJAN ET AL.: "Mechanism of Anmgiotensin-II-induced proliferation in adrenocortical cells", ENDOCRINOLOGY, vol. 131, no. 3, September 1992 (1992-09-01), pages 1174 - 1180, XP000601236 *
See also references of WO9518609A1 *

Also Published As

Publication number Publication date
EP0621895A4 (en) 1996-11-27
EP0696193A1 (fr) 1996-02-14
EP0621895A1 (fr) 1994-11-02
AU674339B2 (en) 1996-12-19
JPH07500254A (ja) 1995-01-12
AU4840393A (en) 1994-03-29
CA2077461A1 (fr) 1994-03-01
AU7090694A (en) 1995-08-01
WO1995018609A1 (fr) 1995-07-13
WO1994005777A1 (fr) 1994-03-17
CA2077461C (fr) 2000-02-15

Similar Documents

Publication Publication Date Title
CA2109084A1 (fr) Methode de destruction de films biologiques
EP1238667A3 (fr) Utilisation des benzothiophènes pour le traitement de l'hypercholestérolemie
AU6613896A (en) Chemical compounds
AU8040391A (en) A process for the preparation of an agent with the active substance flupirtine to combat muscular tension and the use of flupirtine for such purpose
CA2177868A1 (fr) Procede de fabrication de culottes de proprete a ceinture elastique integree
NO942813D0 (no) Spröytekjölt nabumeton
AU7128196A (en) Synergistically active herbicidal mixtures
ZA9510727B (en) 2-¬(Dihydro) pyrazol-3'-yloxymethylene¾ anilides their preparation and their use
PT907365E (pt) Nova formulacao
HU9302628D0 (en) Polypropyleneoxy/polyethyleneoxi copolymers having increased biological activity
FI970747A (fi) Yhdistelmävalmiste käytettäväksi immunologisissa sairauksissa
AU6801496A (en) Film for the treatment of soils by fumigation
WO1995018609A1 (fr) 12-lipoxygenase de leucocytes humains, mediation exercee par la voie metabolique de cette enzyme et consequences de cette action
AU6335496A (en) Benzothiophene compounds
MD990252A (en) Method of controlling the phytopathogenic diseases of grain crops and the fungicidal composition containing 4-phenoxychinoline
AU3396893A (en) Pulsimeter capable of properly evaluating amount of exercise at arbitrary time
AU1669092A (en) Use of torasemide for the treatment of cerebral oedema
EP0958835A4 (fr) Remede therapeutique ou preventif contre l'incontinence ou l'elimination urinaire frequente
WO1997024138A3 (fr) Utilisation medicale de proteases
IL142247A0 (en) Method of treating sickle cell disease and thalassemia
AU2811400A (en) Stable formulation containing fumagillin
ATE242224T1 (de) Fungizide aza-heterocycloalkene
TW342311B (en) Fungicidal mixtures
EP0357351A3 (fr) Compositions de traitement
CA2240392A1 (fr) Formes multimeres de il-16, leur procede de fabrication et leur utilisation

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19950920

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): DE FR GB

A4 Supplementary search report drawn up and despatched

Effective date: 19961014

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): DE FR GB

17Q First examination report despatched

Effective date: 20000522

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61P 35/00 B

Ipc: 7G 01N 33/564 B

Ipc: 7C 12Q 1/26 B

Ipc: 7C 12N 9/02 B

Ipc: 7A 61K 38/46 B

Ipc: 7A 61K 38/28 B

Ipc: 7A 61K 31/155 B

Ipc: 7A 61K 31/44 B

Ipc: 7A 61K 31/34 A

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20050426